Description: SIGA Technologies, Inc. is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company’s lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug that targets orthopoxvirus infections. While TPOXX® is not yet approved as safe and effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug of which 2 million courses have been delivered to the Strategic National Stockpile under Project BioShield.
Home Page: www.siga.com
SIGA Technical Analysis
31 East 62nd Street
New York,
NY
10065
United States
Phone:
212 672 9100
Officers
| Name | Title |
|---|---|
| Dr. Phillip Louis Gomez III, M.D., Ph.D. | CEO & Director |
| Mr. Daniel J. Luckshire | Exec. VP, CFO & Sec. |
| Dr. Dennis E. Hruby | Exec. VP & Chief Scientific Officer |
| Ms. Tove C. Bolken | Sr. VP of Operations & Chief Supply Chain Officer |
| Mr. Herb Vloedman | Sr. VP & Chief Information Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 8.547 |
|---|---|
| Trailing PE: | 5.2817 |
| Price-to-Book MRQ: | 3.4079 |
| Price-to-Sales TTM: | 2.584 |
| IPO Date: | 1997-09-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |